Literature DB >> 9311505

AutoSet nasal CPAP titration: constancy of pressure, compliance and effectiveness at 8 month follow-up.

H Teschler1, A A Farhat, V Exner, N Konietzko, M Berthon-Jones.   

Abstract

We have previously shown that AutoSet satisfactorily improves sleep-disordered breathing and sleep architecture in subjects with obstructive sleep apnoea (OSA) syndrome. The aim of this study was to determine, in subjects treated with long-term conventional fixed pressure continuous positive airway pressure (CPAP) at the AutoSet recommended pressure, whether: the long-term compliance is satisfactory; the improvement persists once initial rebound is over; the titration pressure is stable with time; and the titration pressure is comparable with manual titration pressure using a similar end-point. Twenty males with OSA, previously studied with full polysomnography on their diagnostic night, at manual and AutoSet titration, and at the AutoSet recommended fixed pressure, were re-studied after a mean of 3 and 8 months of treatment at the recommended fixed pressure. Re-study included home respiratory monitoring (Nellcor EdenTrace), and repeated manual and AutoSet titration with polysomnography. Compliance was assessed with hour-meter readings. Mean (+/-SEM) usage was 5.7 +/- 0.1 h.night-1 at 3 and 8 months. The arousal index remained normalized. Diagnostic respiratory disturbance index (RDI) was 60.3 +/- 5.7 events.h-1. On AutoSet at fixed CPAP, RDI was initially 2.6 +/- 0.7 events.h-1, then rose slightly (p < 0.001) to 4.3 +/- 0.6 events.h-1 at 3 months, and was 3.6 +/- 0.5 events.h-1 at 8 months. AutoSet titration pressure was: 9.9 +/- 0.4 cmH2O initially, 10.6 +/- 0.4 cmH2O at 3 months, and 9.7 +/- 0.5 cmH2O at 8 months (NS). Manual titration pressure at 8 months was 10.4 +/- 0.4 cmH2O. The standard deviation of the discrepancy with AutoSet was 0.84 cmH2O. In conclusion, the AutoSet recommended pressure varies little with time, and closely predicts the final manual titration pressure; the improvement in respiratory disturbance index was largely maintained, and compliance was good, although probably enhanced by close supervision.

Entities:  

Mesh:

Year:  1997        PMID: 9311505     DOI: 10.1183/09031936.97.10092073

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

1.  CPAP compliance in sleep apnea patients with and without laboratory CPAP titration.

Authors:  Melanie K Means; Jack D Edinger; Aatif M Husain
Journal:  Sleep Breath       Date:  2004-03       Impact factor: 2.816

2.  Predictive equations for CPAP titration in OSAS patients.

Authors:  Donato Lacedonia; Roberto Sabato; Giovanna E Carpagnano; Pierluigi Carratù; Antonio Falcone; Felice Gadaleta; Onofrio Resta; Maria P Foschino Barbaro
Journal:  Sleep Breath       Date:  2011-01-06       Impact factor: 2.816

Review 3.  Sleep.7: positive airway pressure therapy for obstructive sleep apnoea/hypopnoea syndrome.

Authors:  P Gordon; M H Sanders
Journal:  Thorax       Date:  2005-01       Impact factor: 9.139

4.  Comparison of two in-laboratory titration methods to determine effective pressure levels in patients with obstructive sleep apnoea.

Authors:  M P Bureau; F Sériès
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

5.  Outcome of CPAP Titration for Moderate-to-Severe OSA Under Drug-Induced Sleep Endoscopy: A Randomized Controlled Crossover Trial.

Authors:  Tsai-Yu Wang; Yu-Chen Huang; Ting-Yu Lin; Yung-Lun Ni; Yu-Lun Lo
Journal:  Front Neurol       Date:  2022-06-13       Impact factor: 4.086

6.  Auto-adjusting positive airway pressure in children with sickle cell anemia: results of a phase I randomized controlled trial.

Authors:  Melanie J Marshall; Romola S Bucks; Alexandra M Hogan; Ian R Hambleton; Susan E Height; Moira C Dick; Fenella J Kirkham; David C Rees
Journal:  Haematologica       Date:  2009-07       Impact factor: 9.941

7.  Obstructive sleep apnea - management update.

Authors:  Craig A Hukins
Journal:  Neuropsychiatr Dis Treat       Date:  2006-09       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.